Zydus Lifesciences shares rose over 2% in early morning trade following a major announcement by the company regarding its subsidiary’s strategic move in the US pharmaceutical market. The subsidiary has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV for Ozanimod Capsules, the generic version of Zeposia®, targeting the United States.
Under the terms of the agreement, Synthon BV will handle regulatory approvals, manufacturing, and supply of Ozanimod Capsules. Zydus Lifesciences, in turn, will take charge of commercializing the product across the US. Synthon, being one of the first filers, has already received tentative approval from the US Food and Drug Administration (FDA) and is positioned to benefit from the 180-day exclusivity period upon launch.
Ozanimod, marketed as Zeposia®, is a sphingosine 1-phosphate receptor modulator used to treat relapsing forms of multiple sclerosis (MS) and moderately to severely active ulcerative colitis (UC) in adults. The US market for Ozanimod Capsules is projected to be worth around USD 637 million as of July 2025, highlighting the significant revenue potential for Zydus Lifesciences.
Zydus Lifesciences stock saw a high of ₹1,036 in today’s trading session, up from the previous close of ₹1,011.95, while opening at ₹1,022. The 52-week trading range of the stock remains between ₹795 and ₹1,135.10.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
